03.04.2023 13:28:04
|
EQS-CMS: PharmaSGP Holding SE: Release of a capital market information
EQS Post-admission Duties announcement: PharmaSGP Holding SE
/ Disclosure pursuant to Art. 5 Sec. 1 lit. b) and Sec. 3 of the Regulation (EU) No 596/2014 (MAR) in conjunction with Art. 2 Sec. 2 and Sec. 3 of the Commission Delegated Regulation (EU) No 2016/1052 13th Interim Announcement
Disclosure pursuant to Art. 5 Sec. 1 lit. b) and Sec. 3 of the Regulation (EU) No 596/2014 (MAR) in conjunction with Art. 2 Sec. 2 and Sec. 3 of the Commission Delegated Regulation (EU) No 2016/1052 13th Interim Announcement In the period from March 27, 2023 up to and including March 31, 2023, PharmaSGP Holding SE bought back a total of 545 shares of PharmaSGP Holding SE under the share buyback program; on January 3, 2023, PharmaSGP Holding SE disclosed pursuant to Art. 2 Sec. 1 of the Commission Delegated Regulation (EU) No 2016/1052 the beginning of the share buyback on January 4, 2023. The overall volume of the shares bought back daily in the period from March 27, 2023 up to and including March 31, 2023 and the daily volume-weighted average stock market prices of the shares are as follows:
The total number of shares which have been bought back under the buyback program from January 4, 2023 up to and including March 31, 2023 thus amounts to 5,357 shares. The purchase of the PharmaSGP Holding SE shares was carried out by a bank commissioned by PharmaSGP Holding SE and exclusively via the Frankfurt Stock Exchange (XETRA trading). More detailed information pursuant to Art. 5 Sec. 1 lit. b) and Sec. 3 of the Regulation (EU) No 596/2014 in conjunction with Art. 2 Sec. 2 and Sec. 3 of the Commission Delegated Regulation (EU) No 2016/1052 is available on the internet at https://ir.pharmasgp.com at share buyback 2023. Gräfelfing, March 31, 2023 PharmaSGP Holding SE
03.04.2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | PharmaSGP Holding SE |
Lochhamer Schlag 1 | |
82166 Gräfelfing | |
Germany | |
Internet: | https://pharmasgp.com |
End of News | EQS News Service |
|
1599745 03.04.2023 CET/CEST
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu PharmaSGPmehr Nachrichten
27.11.24 |
Ausblick: PharmaSGP legt Quartalsergebnis vor (finanzen.net) | |
25.11.24 |
EQS-DD: PharmaSGP Holding SE: FUTRUE GmbH, Kauf (EQS Group) | |
25.11.24 |
EQS-DD: PharmaSGP Holding SE: FUTRUE GmbH, buy (EQS Group) | |
14.11.24 |
EQS-News: PharmaSGP with strong revenues growth in 9M 2024 – revenues forecast for FY 2024 raised (EQS Group) | |
14.11.24 |
EQS-News: PharmaSGP mit kräftigem Umsatzwachstum in 9M 2024 – Erhöhung der Umsatzprognose für FY 2024 (EQS Group) | |
05.11.24 |
EQS-News: CEO-Wechsel bei der PharmaSGP Holding SE: Peter Gerckens folgt zum 01. Januar 2025 auf Natalie Weigand (EQS Group) | |
05.11.24 |
EQS-News: CEO change at PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as of January 1, 2025 (EQS Group) | |
05.11.24 |
EQS-Adhoc: PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer (EQS Group) |